Policy paper

G7 Finance Ministers’ Statement on Actions to Support Antibiotic Development

G7 Finance Ministers have today (13 December 2021) agreed a G7 statement on Actions to Support Antibiotic Development, aiming to strengthen G7 preparedness against the “silent pandemic” of antimicrobial resistance.

This was published under the 2019 to 2022 Johnson Conservative government

Documents

G7 Finance Ministers’ Statement on Actions to Support Antibiotic Development

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email digital.communications@hmtreasury.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Annex A – Examples of G7 actions to create the right economic conditions to preserve existing antibiotics and their access, strengthen antibiotic research and development, and bring new drugs to market

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email digital.communications@hmtreasury.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

G7 Shared Principles for the Valuation of Antimicrobial Therapeutics

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email digital.communications@hmtreasury.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

All G7 members recognise antimicrobial resistance (AMR) as requiring a multi-year and multi-stakeholder effort.

All G7 members have committed to expedite the implementation of their existing AMR Action Plans and related strategies, and to take additional specific and appropriate steps to address antibiotic market failure and create the right economic conditions to preserve essential existing antibiotics and ensure their access, strengthen AMR antibiotic research and development, and bring new drugs to market where they meet identified public health needs.

See the Annex for examples of G7 action.

Updates to this page

Published 13 December 2021

Sign up for emails or print this page